...
首页> 外文期刊>Medicinski Preglad >Body mass index in asthmatic children before and after one year inhaled glucocorticosteroids therapy BMI
【24h】

Body mass index in asthmatic children before and after one year inhaled glucocorticosteroids therapy BMI

机译:吸入糖皮质激素治疗BMI前后一年的哮喘儿童体重指数

获取原文

摘要

Introduction. Asthma is the most frequent children’s disease, with a tendency of further growth. Bearing in mind controversial data on obesity of asthmatic children and a possible effect of inhaled corticosteroids (ICS) on children’s growth, the aim of our study was to determine the body mass index (BMI) in asthmatic children at the beginning of the therapy and to study the effect of the continuous application of ICS on growth and BMI during the period of 1 year. Material and methods. The study included 100 children aged 7 to 18 diagnosed to have partly controlled and uncontrolled allergic asthma, who were continuously given ICS as a prevention against asthma attacks at Pediatric Clinic of the Clinical Center in Kragujevac for the period of 1 year. Children with BMI p97 as obese. Results. The highest percentage of children with asthma was within normal parameters (70%), 10% of the children were underweight (boys: n=8/60, 13.3% vs. girls: n=2/40, 5%), and 18% were overweight/obese. Monovariable analysis of variant with repeated measurements have shown a statistically significant difference in the height of children in all age groups after a year of continuous therapy of ICS (p=0.000), except in girls aged 15-18, who did not show any significant difference in body height after the therapy (p>0.05). Conclusion. Asthmatic children with partly controlled and uncontrolled asthma have mostly normal BMI and ICS can be safely administered in asthmatic children.
机译:介绍。哮喘是儿童中最常见的疾病,有进一步发展的趋势。考虑到哮喘儿童肥胖的争议数据以及吸入糖皮质激素(ICS)可能对儿童生长的影响,我们的研究目的是在治疗开始时确定哮喘儿童的体重指数(BMI),并研究了连续1年服用ICS对生长和BMI的影响。材料与方法。该研究包括100名7至18岁的被诊断为部分控制和未控制的过敏性哮喘的儿童,他们在克拉古耶瓦茨临床中心的儿科诊所连续1年接受ICS预防哮喘发作。肥胖的BMI p97儿童。结果。哮喘儿童的最高百分比在正常参数范围内(70%),体重不足的儿童占10%(男孩:n = 8 / 60,13.3%,女孩:n = 2 / 40,5%)和18 %超重/肥胖。重复测量的变量单变量分析显示,在接受ICS连续治疗一年后,所有年龄段儿童的身高在统计学上均存在显着差异(p = 0.000),但15-18岁的女孩则没有显着差异。治疗后身高的差异(p> 0.05)。结论。具有部分控制和不受控制的哮喘的哮喘儿童多数BMI正常,哮喘儿童可以安全服用ICS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号